The response of diffuse noxious inhibitory controls (DNIC) is often decreased, or lost, in stress-related functional pain syndromes. Because the dynorphin/kappa opioid receptor (KOR) pathway is activated by stress, we determined its role in DNIC using a model of stress-induced functional pain. Male, Sprague-Dawley rats were primed for 7 days with systemic morphine resulting in opioidinduced hyperalgesia. Fourteen days after priming, when hyperalgesia was resolved, rats were exposed to environmental stress and DNIC was evaluated by measuring hind paw response threshold to noxious pressure (test stimulus) after capsaicin injection in the forepaw (conditioning stimulus). Morphine priming without stress did not alter DNIC. However, stress produced a loss of DNIC in morphine-primed rats in both hind paws that was abolished by systemic administration of the KOR antagonist, nor-binaltorphimine (nor-BNI). Microinjection of nor-BNI into the right, but not left, central nucleus of the amygdala (CeA) prevented the loss of DNIC in morphine-primed rats. Diffuse noxious inhibitory controls were not modulated by bilateral nor-BNI in the rostral ventromedial medulla. Stress increased dynorphin content in both the left and right CeA of primed rats, reaching significance only in the right CeA; no change was observed in the rostral ventromedial medulla or hypothalamus. Although morphine priming alone is not sufficient to influence DNIC, it establishes a state of latent sensitization that amplifies the consequences of stress. After priming, stress-induced dynorphin/KOR signaling from the right CeA inhibits DNIC in both hind paws, likely reflecting enhanced descending facilitation that masks descending inhibition. Kappa opioid receptor antagonists may provide a new therapeutic strategy for stress-related functional pain disorders.
Introduction
Functional pain syndromes (FPS) occur without identifiable noxious stimulus or injury and include diverse conditions such as fibromyalgia, irritable bowel syndrome, migraine, medication overuse headache, and others. 1, 6, 14, 20, 40, 44, 46, 60, 61, 65, 77, 78 The mechanisms underlying FPS are not well understood and although differences undoubtedly exist between these conditions, it is also likely that there is shared and overlapping biology. Stress is commonly identified as a "trigger" of FPS. 27, 31, 36, 54, 67, 75, 76 Repeated, severe, or uncontrolled stress can elicit maladaptive dysregulation that alters brain networks to promote sensitized states (ie, "allostatic overload"). 3, 55 Repeated stress may increase vulnerability to pain attacks and promote transformation from episodic to chronic pain. 17, 53 Frequency of attacks, pain intensity, and the presence of allodynia (ie, enhanced responses to normally innocuous stimuli) have been suggested as factors promoting increased risk of pain chronification. 6, 70 An additional factor linked to pain chronification is net diminished conditioned pain modulation (CPM) 22, 87, 91 or diffuse noxious inhibitory controls (DNIC). The DNIC response is a pain-inhibits-pain phenomenon, originally discovered in rats. 2 In humans, DNIC/CPM is demonstrated by the concurrent application of noxious conditioning and test stimuli to different locations on the body. The application of the conditioning stimulus increases the pain threshold (ie, produces analgesia) to the test stimulus in subjects with efficient DNIC/CPM reflecting a "bottom-up" modulation of pain through engagement of descending inhibition. 92 Patients with a lower CPM response, measured before scheduled surgery, were significantly more likely to develop chronic postoperative pain. 43, 93 Similarly, postoperative hypersensitivity took longer to resolve in rats with a lower presurgery DNIC response 69 ; suggesting that the DNIC/CPM response may serve as a prospective measure of vulnerability for pain chronification. 92 Critically, the CPM response has been shown to be lost or diminished in patients suffering from chronic pain, including individuals with FPS. 1, 14, 20, 40, 44, 46, 60, 61, 65, 77, 78 Although stress elicits a multitude of physiological responses, it is now understood that dynorphin, an endogenous kappa opioid receptor (KOR) agonist, is a key mediator in central stress circuits. Stress-induced activation of KORs has been shown to promote negative affective states, including depression and anxiety, as well as relapse to drug seeking in addiction. 7, 15, 16, 41, 47 Antagonism of KOR signaling with nor-binaltorphimine (nor-BNI), a KOR antagonist, blocks aversive behaviors to stress. 42 Kappa opioid receptors are found in multiple brain regions that are relevant to pain, including the central nucleus of the amygdala (CeA). 12, 41, 50 The amygdala is a limbic brain area that plays a key role in emotional responses and affective states and disorders including learned fear, anxiety, depression, and pain. 62 Although outputs from the CeA project to descending pain modulatory pathways including the periaqueductal gray (PAG), and ultimately to the spinal cord through the rostral ventromedial medulla (RVM), the potential influences of the amygdala on the DNIC response remain relatively unstudied.
We investigated whether stress-related CeA KOR signaling promotes functional pain by measuring DNIC after hyperalgesic priming with morphine. We demonstrate a lateralized KORdependent mechanism in the CeA that mediates a generalized loss of DNIC after stress, suggesting new strategies for therapy.
Methods

Animals
A total of 176 male, Sprague-Dawley rats (175-200 g; Envigo, Indianapolis, IN) were used in these studies. Experiments were conducted in accordance with policies set forth by the NIH guidelines for use of laboratory animals and approval from the IACUC at the University of Arizona. Rats were kept in a climate controlled room on a 12-hour light and 12-hour dark cycle with ad libitum access to food and water. We adhered to the ARRIVE guidelines wherever possible. Animals were randomly assigned to experimental groups and the experimenters were blinded to the treatments. A post hoc power analysis was performed using G*Power software 25 to verify that group sizes were sufficient to detect significant effects.
Morphine priming
Anesthesia was briefly induced with 5% isoflurane and maintained with 2% isoflurane to allow for subcutaneous (s.c.) implantation of osmotic minipumps (Model 2001; Alzet, Cupertino, CA) (1 mL/h) delivering vehicle (0.9% saline; VetOne, Boise, ID) or morphine sulfate (7.68 mg·kg 21 ·d 21 ) for 7 days. The experimenter was blinded to the treatment that the rats received. This dose and method of administration was chosen because it has previously been reported to cause neurons in the dorsal medullary horn to have increased receptive field size, increased activity to noxious heat stimuli, and a decreased threshold to activate mechanical and electrical stimulation. 64 Anesthesia duration was approximately 5 minutes. Gentamycin (8 mg/kg; VetOne) was administered once immediately after surgery.
Cannulation surgery
Stereotaxic surgeries were performed in anesthetized rats using intraperitoneal (i.p.) ketamine and xylazine cocktail (80 mg/kg ketamine; Western Medical Supply, Arcadia, CA and 12 mg/kg xylazine; Sigma-Aldrich, St. Louis, MO). For all experiments that required targeting of specific brain areas, a cannula (26 gauge; PlasticsOne, Roanoke, VA) was implanted on day 10 or 11 after minipump implantation. Coordinates for cannula placement were chosen from a brain atlas. 68 For CeA cannulations, a single-guide cannula was implanted into the CeA (64.0-mm mediolateral, 22.0-mm anteroposterior, and 26.0-mm dorsoventral from bregma). For RVM cannulations, a double-guide cannula (1.2-mm spacing between cannula) was centered over the midline and implanted at 2.0-mm posterior to the intra-aural line and 8.0-mm ventral from the skull. Central nucleus of the amygdala and RVM injectors extended 1 mm below the cannula. Surgeries lasted approximately 30 minutes and rats typically recovered from anesthesia around 1 hour after administration of the anesthetic. Gentamycin (8 mg/kg; VetOne) was administered once during the immediate postoperative period.
Kappa opioid receptor antagonist
Rats used for systemic studies received s.c. injection of the KOR antagonist, nor-binaltorphimine (nor-BNI, 3 mg/kg, 1 mL/kg; Tocris, Bristol, United Kingdom), or vehicle (0.9% saline, 1 mL/ kg). Rats used for intra-amygdala or RVM studies received nor-BNI (2.5 mg in 0.5 mL per site) or vehicle (0.5 mL per site of 0.9% saline) through the cannula. All nor-BNI or vehicle injections were given 1 hour before each environmental bright light stress session and the experimenter was blinded to the assigned treatment group. Although nor-BNI administration has been shown to cause long-term KOR inactivation 9, 24, 30, 32, 37 that exceeds the 24-hour period between stress sessions, we gave 1 dose 1 hour before each environmental bright light stress to ensure that KORs were maximally blocked before each stress session.
Environmental bright light stress
On days 20 and 21, postpump implantation rats received bright light stress (BLS) as described previously. 29 Briefly, rats were placed, unrestrained, in plexiglass caging and halogen shop lamps were placed on the left and right sides of the cages to reach an illumination of approximately 1400 lux inside the cages. Rats were exposed to the bright lights for 1 hour before transfer to chambers for testing. Days 20 and 21 after morphine priming were chosen to insure that sensory thresholds had returned to premorphine levels reflecting resolution of opioid-induced hyperalgesia (OIH).
Tactile sensory thresholds
Sensory thresholds were measured during and after administration of s.c. morphine. Rats were tested using a series of von Frey filaments (Touch Test sensory evaluators; Stoelting, Wood Dale, IL) and withdrawal threshold was calculated using the Dixon updown method. 23 Hind paw withdrawal threshold was tested by perpendicular application of the filaments to the plantar surface of both hind paws and periorbital withdrawal threshold was tested by applying the filaments to the center of the forehead. Left and right hind paw withdrawal thresholds were averaged before data analysis. Cutoff was 15 g for hind paw and 8 g for periorbital measurements.
Conditioning stimulus
An intradermal capsaicin (Sigma-Aldrich) injection was chosen as the conditioning stimulus to induce the DNIC response. Capsaicin was prepared as previously described. 26 Briefly, capsaicin was dissolved in 1:1 tween 80 (Sigma-Aldrich) and 100% ethanol (Decon Laboratories, King of Prussia, PA) to an initial concentration of 50 mg/mL. Capsaicin was then diluted to the final concentration (2.5 mg/mL) with 0.9% saline. Capsaicin solution was prepared 40 minutes before injection and was stored at 220˚C until injection. Two hours after the second episode of BLS, rats were briefly anesthetized with isoflurane (duration less than 2 minutes) and injected with 50 mL (125 mg) of capsaicin intradermally into the left forepaw.
Test stimulus
The Randall-Selitto (RS) paw pressure test (Ugo Basile, Varese, Italy) was used to measure analgesia or hyperalgesia. An increasing pressure was applied to the rat hind paw until there was a withdrawal response (cutoff at 500 g). The pressure applied when the rat withdrew its paw was recorded as the paw withdrawal threshold (PWT). In our model, it serves as the test stimulus to measure the DNIC response after application of the conditioning stimulus. Before minipump implantation, the RS baseline PWT measurement was taken. On day 7 after pump implantation, a second PWT measurement was taken. After a further 14 days and before BLS, rats were evaluated to confirm recovery from OIH demonstrated by a return to baseline PWT. On day 21, 2 hours after BLS, a precapsaicin injection baseline measure was taken, followed by the immediate injection of capsaicin into the left forepaw and the beginning of the DNIC timecourse measurements. Paw withdrawal threshold was measured 3 times for each paw at each timepoint and averaged before data analysis.
Cannula verification
At the end of the in vivo experiments, rats were euthanized and injected with 0.5 mL of Higgins Black Magic ink (Chartpak, Leeds, MA) into the cannula for visual confirmation of injection site. Brains were harvested and fixed using 10% formalin for a period of 24 hours. Coronal sections (30-mm thick) from the brain area of interest were cut using a Microm HM 525 cryostat and mounted on Superfrost Plus microscope slides (Fisher Scientific, Pittsburgh, PA). Coronal brain sections were cross-matched with a brain atlas 68 to confirm cannula placement. In total, 4 rats were excluded from the amygdala studies because of cannula locations being outside the amygdala upon verification. Two rats in the left CeA experiment (1 morphine/vehicle and 1 saline/nor-BNI) were excluded because of cannula location in the caudate putamen and 2 rats in the right CeA experiment (1 saline/vehicle and 1 saline/nor-BNI) were excluded for the same reason.
Dynorphin A EIA
Rats were pretreated with morphine sulfate or vehicle as described above. Rats received BLS and the DNIC response was evoked as described above. After measuring the DNIC response at the 20-minute postcapsaicin timepoint, rats were deeply anesthetized with 5% isoflurane and decapitated. Tissue punches of left and right CeA, hypothalamus, and RVM were taken. Brains were placed upside down in a brain matrix and slices were taken at 22 to 23 mm from the optic chiasm for amygdala and hypothalamus collection and 210 to 212 mm for RVM. Tissue punches were taken from these slices (1-mm diameter for amygdala and 2-mm diameter for hypothalamus and RVM). Hypothalamus and RVM tissue was solubilized in 100 mL/ g PBS that contained a peptidase and phosphatase inhibitor cocktail (Halt; Thermo Scientific, Rockford, IL). Amygdala tissue samples were solubilized in 150 mL/g solution to obtain sufficient supernatant volume to run the EIA kit according to the manufacturer protocol. All tissue samples were homogenized by sonication followed by heating to 95˚C for 10 minutes. Samples were then centrifuged at 4˚C and 10,000 rcf for 20 minutes. Dynorphin A content was measured using an EIA kit (Peninsula Laboratories, San Carlos, CA). A Micro BCA (bicinchoninic acid) Protein Assay Kit (Thermo Scientific, Waltham, MA), an assay for total protein, was also run to standardize the samples for varying amounts of tissue by expressing the dynorphin A content as percent of total protein. For the micro BCA assay, samples were diluted 1:10 so that readings would fall in the linear range of the standard curve.
Statistics
Tactile sensory thresholds (von Frey) timecourses, 20-minute DNIC data for nor-BNI experiments, and timecourse data used for the assessment of the effects of stress on DNIC were analyzed using 2-way analysis of variance (ANOVA) followed by Tukey test for multiple comparisons. Diffuse noxious inhibitory controls' timecourses for the assessment of the effects of nor-BNI on the DNIC response were analyzed using 3-way ANOVA and Sidak correction for multiple comparisons was applied. Data shown as percent maximal response were calculated by subtracting the baseline value from the test point value and dividing by the cutoff value (500 g) minus the baseline value. Dynorphin A EIA results were measured using multiple t tests without the assumption of equal variance and the DNIC responses of rats used for EIA studies were analyzed using t test with Welch correction. Threeway ANOVA data were analyzed using SPSS and all other data were analyzed using GraphPad Prism 7 software.
Results
Morphine priming produces transient hypersensitivity
Delivery of morphine by s.c. minipumps produced time-related and reversible hypersensitivity to innocuous tactile stimuli (von Frey test). Morphine-treated rats exhibited significant tactile periorbital ( Fig. 1A , P 5 0.0225; F (1,31) 5 5.765) and hind paw (Fig. 1B , P , 0.0001; F (1,99) 5 113.4) allodynia that was apparent by day 4 (periorbital: P 5 0.0047, hind paw: P , 0.0001) and reached maximal levels within 7 days (periorbital and hind paw: P , 0.0001). Both periorbital and hind paw allodynia resolved approximately 11 days after the end of morphine treatment.
Paw withdrawal threshold to a noxious mechanical stimulus (RS test) was evaluated in a separate cohort of rats. Morphinetreated rats, but not saline-treated, showed a significant decrease in the RS PWT in either hind paw when tested on day 7 ( Fig. 1C , P , 0.0001; F (1,320) 5 30.03). Measurements of PWT from the left and right hind paws of each rat were averaged for each animal and the average was used to calculate the overall hyperalgesic score for the treatment group. The observed hyperalgesia resolved approximately 1 week after the end of morphine treatment (day 14, P 5 0.8135, unpaired t test, data not shown). In rats previously implanted with cannulas, the PWT was tested on day 20 (just before the first stress exposure) and was not significantly different from premorphine levels at this timepoint (P 5 0.2163, unpaired t test, data not shown).
Stress reinstates allodynia only in morphine-primed rats
In rats previously exposed to morphine, exposure to a period of environmental stress resulting from bright lights (ie, BLS) reinstated tactile allodynia. Morphine-primed rats showed 2D , P , 0.0001; F (1,78) 5 199.1) regions that was greater in magnitude and longer lasting than that observed on day 20; the periorbital allodynia was significant from 2 to 4 hours (2: P 5 0.0001, 3: P 5 0.0009, 4: P 5 0.0037) and hind paw allodynia extended beyond the 6-hour timecourse (hours 1-5: P , 0.0001, 6: P 5 0.0016) of the measurements (Figs. 2C and D) . No significant changes in tactile thresholds were observed in rats previously treated with saline.
Stress impairs diffuse noxious inhibitory controls in morphine-primed rats
Two hours after the second BLS exposure, the DNIC response was induced by intradermal forepaw capsaicin injection (ie, the conditioning stimulus) and followed by the evaluation of the RS PWT (ie, the test stimulus) (see Fig. 3A for timecourse). Diffuse noxious inhibitory controls were demonstrated by an increase in paw withdrawal thresholds (ie, analgesia). After stress, the DNIC response was significantly impaired or lost in morphine-primed animals compared with animals treated with saline ( Fig. 3B , P , 0.0001; F (1,25) 5 35.35). Notably, morphine priming alone, without exposure to stress, did not alter the DNIC response (Fig. 3C) suggesting a requirement for both priming and stress in the modulation of this response.
Systemic kappa opioid receptor blockade prevents the stress-induced loss of diffuse noxious inhibitory controls in morphine-primed rats
Rats primed with morphine and exposed to BLS exhibited a significant loss of DNIC compared with saline-primed rats in the left (P 5 0.0049; F (1, 31) (Fig. 3D) or right ( Fig. 3E ) hind paw and no effect of systemic nor-BNI was observed when both hind paws were averaged in saline-primed rats (Fig. 3F) . By contrast, nor-BNI significantly prevented the loss of the DNIC response after stress that was observed in morphine-primed rats in the left (Fig. 3D) , right (Fig. 3E) , and averaged ( Fig. 3F) hind paw responses. There was a significant interaction between priming and treatment (P 5 0.0225; F (1,31) 5 5.765) at the 20-minute timepoint (Fig. 3G) and post hoc analysis reveals that nor-BNI treatment significantly prevented the stress-induced loss of DNIC in morphine-primed rats (P 5 0.0126). These results show that KOR antagonism prevents stress-induced loss of DNIC in morphine-primed rats. A and B) . Morphine-treated rats also showed hind paw hyperalgesia on the RS test on day 7 of drug treatment compared with morphine-treated baseline measures and compared with saline rats on day 7 (C). ****P , 0.0001, ***P , 0.001, **P , 0.01, *P , 0.05 significant difference compared with baseline or as indicated. Allodynia experiments (A and B) n 5 7 per group, and RS experiment (C) n 5 98 saline, 64 morphine (data combined from rats used in all experiments in this article). Data analyzed using 2-way analysis of variance followed by Tukey test for multiple comparisons. BL, baseline; WT, withdrawl threshold. Figure 2 . Bright light stress reinstates hypersensitivity in morphine-primed rats. Morphine-primed rats showed periorbital (A and C) and hind paw (B and D) allodynia to von Frey filaments after the first (day 20, A and B) and second (day 21, C and D) bright light stress session. ****P , 0.0001, ***P , 0.001, **P , 0.01, *P , 0.05. n 5 7 per group. Data analyzed using 2-way analysis of variance followed by Tukey test for multiple comparisons. BL, baseline; WT, withdrawl threshold.
3.5. Kappa opioid receptor blockade in the right central nucleus of the amygdala prevents stress-induced loss of diffuse noxious inhibitory controls in morphine-primed rats
In rats that received right CeA cannulations, DNIC was significantly greater after BLS in saline-primed than in morphine-primed rats. This effect of priming was observed in the left (Fig. 4A , P , 0.0001; F (1,23) 5 20.988), right ( Fig. 4B , 6.942) hind paw measurements and post hoc analysis showed that morphine-primed rats with nor-BNI microinjected into the right CeA before BLS had significantly greater DNIC responses than morphine-primed rats that had vehicle microinjected before BLS and this effect was observed in the left (Fig. 4A) , right (Fig.  4B) , and averaged (Fig. 4C) hind paw measurements, showing that blockade of KOR signaling in the right CeA significantly prevents stress-induced loss of DNIC response bilaterally after morphine priming. Nor-BNI did not significantly alter the DNIC response in saline-primed rats (Figs. 4A-C) . At the 20-minute timepoint (Fig. 4D) , there was a significant interaction between priming and treatment (P 5 0.0219; F (1,23) 5 6.041) and post hoc analysis showed that right CeA nor-BNI treatment significantly prevented the stress-induced loss of DNIC in morphine-primed rats (P 5 0.0342).
Kappa opioid receptor blockade in the left central nucleus of the amygdala does not prevent stress-induced loss of diffuse noxious inhibitory controls in morphineprimed rats
Morphine-primed rats with left CeA cannulas had a significantly lower DNIC response than saline-primed rats in the left (Fig. 5A, 5C , P , 0.0001; F (1,28) 5 25.600) hind paw measurements after BLS. In contrast to the right CeA results, microinjection of nor-BNI into the left CeA 1 hour before each BLS session did not alter the stress-induced loss of DNIC in morphine-primed rats. Microinjection of nor-BNI into the left CeA also did not alter the DNIC response of saline-primed rats. These effects were observed in the left (Fig. 5A) , right (Fig. 5B) , and averaged ( Fig. 5C ) hind paw responses. Morphine priming caused a significant loss of DNIC at the 20-minute timepoint ( Fig. 5D , P , 0.0001; F (1,28) 5 25.33). The effect of nor-BNI or vehicle pretreatment on the loss of DNIC was not significant, nor was the interaction between priming and treatment. These data suggest that KOR signaling in the right, but not the left, CeA promotes the stress-induced loss of DNIC.
Rostral ventromedial medulla nor-binaltorphimine does not restore diffuse noxious inhibitory controls in morphineprimed rats
After BLS, morphine priming caused a loss of DNIC that was not significantly modulated by bilateral administration of nor-BNI into the RVM in the left (Fig. 6A , P 5 0.0272; F (1,23) 5 5.566) and averaged ( Fig. 6C , P 5 0.0376, F (1,23) 5 4.868) hind paw measurements. In the right hind paw measurement (Fig. 6B) , the morphine-primed rats did not have a significantly different DNIC response compared with the saline-primed rats (P 5 0.0711, F (1,23) 5 3.580), but a 2-way ANOVA of left vs right hind paw data also revealed no significant difference between the hind paw measurements of the morphine-primed/nor-BNI injected group at any timepoint. Analysis of the 20-minute timepoint (Fig. 6D ) indicated a reduction of DNIC in both morphine-primed groups that was not restored by nor-BNI; a 2-way ANOVA showed a significant effect of priming (P 5 0.0246; F (1,23) 5 5.787), but neither the effect of RVM pretreatment nor the interaction between priming and pretreatment was significant. Morphine priming followed by stress causes a loss of DNIC that is ameliorated by systemic nor-BNI. A timeline of experimental procedures is shown for clarity (A). Rats primed with morphine that received BLS on day 20 and again at day 21 had a significant loss of DNIC compared with salineprimed rats (B). However, morphine-primed rats that were not exposed to BLS did not have a significantly different DNIC response compared with salineprimed rats (C). Nor-BNI administered subcutaneously before each BLS period significantly attenuated the loss of DNIC in morphine-primed rats (D-F). This effect was observed in the left (D), right (E), and combined left and right (averaged together, F) hind paw measurements. At the 20-minute DNIC timepoint (G), after BLS, the morphine-primed group treated with nor-BNI did not have a significant loss of DNIC, whereas the morphine-primed rats treated with vehicle showed a significant loss of DNIC. Also, the morphine-primed rats treated with nor-BNI showed significantly higher DNIC than morphine-primed vehicle-treated rats (G). ****P , 0.0001, ***P , 0.001, **P , 0.01, *P , 0. 
Stress increases dynorphin A levels in the central nucleus of the amygdala
Possible stress-induced changes in dynorphin levels were measured in a separate cohort of animals. In these rats, we verified that morphine priming and stress produced a loss of the DNIC response measured at 20 minutes after capsaicin injection compared with rats with saline priming (Fig. 7A , P , 0.0001; F (14,13) 5 1.504). Dynorphin A content was measured at 2.5 hours after the second BLS (Fig. 7B) . Dynorphin A content was significantly higher in the right CeA of morphine-primed rats compared with vehicle-primed rats (P 5 0.0227). Dynorphin A content was increased in the left CeA, but did not reach statistical significance (P 5 0.1017). Significant differences in dynorphin content were not observed between saline-primed or morphineprimed groups in the hypothalamus or RVM (P 5 0.1623 and P 5 0.7709, respectively).
Discussion
Functional pain syndromes affect more than 15% of the population worldwide and have been suggested to reflect the interplay between genetic susceptibility, gene-environment interactions, and environmental triggers to elicit a "central sensitivity syndrome." 21 We studied the role of stress in promoting functional pain by adapting the "2-hit" hyperalgesic priming model thought to promote central sensitization relevant to pain chronification. 73 Functional pain syndromes are characterized by pain without obvious organic origin, and are not known to occur naturally in rodents. We treated rats with morphine to induce a hyperalgesic state similar to that seen in FPS syndromes, without use of a noxious stimulus for the initial priming event. Opioids produce long-lasting neural amplification termed OIH in humans 18, 19, 52 and in animals. 48, 79 Chronic pain patients on opiate therapy show increased sensitivity to noxious stimuli and temporal summation accompanied by decreased tolerance to maximal noxious stimuli as well as a loss of DNIC. 94 This study investigated the role of KOR signaling by assessing the DNIC response, a dynamic assessment of pain modulatory mechanisms after morphine priming. We report the loss of DNIC in a preclinical model without injury that requires stress. In addition, we found that the loss of DNIC is mediated through KOR signaling from the right CeA. The involvement of the CeA or of KOR signaling in producing a loss of DNIC has not previously been reported and extends our previous findings on KORmediated modulation of static sensory thresholds after sumatriptan priming. 90 Morphine produced generalized and transient cephalic and extracephalic allodynia in uninjured rats that outlasted the period of drug delivery; thresholds returned to baseline levels within 11 days. Opioid-induced hyperalgesia was also detected in either hind paw using a noxious mechanical stimulus with thresholds returning to predrug baselines within 14 days of termination of the drug. After resolution of OIH, animals with normal sensory thresholds and no tissue injury were hypersensitive to challenge with environmental stress. Uninjured morphine-primed rats showed stress-induced, delayed, and generalized allodynia that Figure 5 . Nor-BNI administered into the left CeA before BLS did not ameliorate the loss of DNIC. Rats primed with morphine had a significant loss of DNIC after BLS in the left (A), right (B), and averaged (C) hind paw measurements compared with vehicle-primed rats in both the vehicle and nor-BNI treatment groups. Administration of nor-BNI into the left CeA before BLS did not alter the loss of DNIC in the left (A), right (B), or averaged (C) hind paw measurements. At the 20-minute DNIC timepoint (D) both morphine-primed groups have significantly less DNIC after BLS than saline-primed controls. ***P , 0.001, **P , 0.01, *P , 0.05 significant difference between the saline/vehicle group and other treatment groups. n 5 10 saline/vehicle, 10 saline/nor-BNI, 6 morphine/vehicle, 6 morphine nor-BNI. Data analyzed using 3-way analysis of variance with Sidak correction for multiple comparisons (A-C) or 2-way analysis of variance followed by Tukey test for multiple comparisons (D). BL, baseline; BLS, bright light stress; CeA, central nucleus of the amygdala; DNIC, diffuse noxious inhibitory controls; nor-BNI, nor-binaltorphimine. Nor-BNI administered into the right CeA before BLS ameliorates the loss of DNIC. After BLS, rats primed with morphine had a significant loss of DNIC compared with vehicle-primed rats in both the vehicle and nor-BNI treatment groups in the left (A), right (B), and averaged (C) hind paw measurements. However, the morphine/nor-BNI treatment group had a significantly higher DNIC response in the left (A), right (B), and averaged (C) than morphine/vehicle when nor-BNI was administered into the right CeA before BLS. At the 20-minute DNIC timepoint (D), the morphine/vehicle group has significantly less DNIC response than the saline/vehicle group after BLS, but the morphine/nor-BNI group does not. In addition, the morphine-primed rats treated with nor-BNI have significantly higher DNIC than the morphineprimed rats treated with vehicle. ****P , 0.0001, ***P , 0.001, **P , 0.01, *P , 0.05 significant difference between the saline/vehicle group and other treatment groups. ####P , 0.0001, ##P , 0.01, #P , 0.05 significant difference between morphine/vehicle and morphine/nor-BNI rats at a timepoint. n 5 6 saline/vehicle, 7 saline/nor-BNI, 6 morphine/vehicle, and 8 morphine nor-BNI. Data analyzed using 3-way analysis of variance followed by Sidak correction for multiple comparisons (A-C) or 2-way analysis of variance followed by Tukey test for multiple comparisons (D). BL, baseline; BLS, bright light stress; CeA, central nucleus of the amygdala; DNIC, diffuse noxious inhibitory controls; nor-BNI, nor-binaltorphimine.
increased in magnitude and duration upon a second stress exposure, possibly consistent with increasing effects of repeated attacks in FPS. 10, 49, 57 Notably, our stress conditions produced mild analgesia in saline-primed animals. However, both the stress-induced analgesic and hyperalgesic effects evaluated with the noxious PWT were relatively small and stress-induced hyperalgesia in morphine-primed rats did not reach significance in this test. This bidirectional response suggests that morphine priming may increase vulnerability to stress-related pain.
The circuits underlying the DNIC response are not fully understood. Whether and how bidirectional modulatory circuits from the RVM participate in this response remains unclear. Noxious stimuli activate RVM ON cells to promote descending facilitation 35, 59 , whereas DNIC engages descending inhibition from the subnucleus reticularis dorsalis (SRD). 5 The observed DNIC may thus reflect the combined contribution of these competing descending circuits. 82 Whether inputs from higher brain centers that are important in pain modulation, such as the cortex, hypothalamus, and amygdala, participate in DNIC remains relatively unstudied. 66 The amygdala participates in stress responses and is a part of the affective pain system. 80 We chose to target the CeA because it receives polymodal information from the basal lateral complex and direct nociceptive input from the brainstem 80 including the SRD, 45 which is necessary to produce the DNIC response. 5, 83, 85 In addition, the CeA sends output to multiple brainstem regions, including the PAG 81 with direct projections to the RVM. Amygdala circuits are activated by stress and we previously found that stress-induced allodynia after morphine priming was blocked by inactivation of the RVM. 79 The dynorphin/KOR system is activated by stress 7, 15, 16, 38, 47 through a hypothesized corticotropin-releasing factor (CRF) to dynorphin to KOR pathway. 7, 8, 34, 38, 42 Kappa opioid receptors are expressed in circuits relevant to pain 12, 41, 50 and stress increases KOR activation in these circuits, including the amygdala. 7, 42 We determined whether systemic, intraamygdala, or intra-RVM KOR blockade would influence stress-induced DNIC in saline-primed or morphine-primed rats. In the absence of stress, DNIC was observed in animals previously primed with saline or with morphine. Although DNIC was not influenced by stress in saline-primed rats, it was lost or greatly diminished after stress in morphine-primed animals. Systemic nor-BNI prevented the stress-induced loss of DNIC in morphine-primed rats suggesting a key role for KORs in this response.
The amygdala has increased activation during CPM assessment in humans. 58, 71, 88 However, whether activity in the amygdala, and specifically in the CeA, modulates DNIC has not been reported. We found that KOR antagonism in the right CeA, but not the left CeA or RVM, prevented the loss of DNIC measured in either hind paw in morphine-primed animals. A lateralized role of the amygdala has been shown in inflammatory 13, 33, 63, 74 and neuropathic pain 28 models and mGluR5 activation in the right, but not left, CeA is sufficient to produce peripheral hypersensitivity in the absence of injury. 39 Recently, we demonstrated that microinjection of a KOR agonist into the right, but not left, CeA produced allodynia in both hind paws after priming with sumatriptan to model medication overuse headache. 90 Collectively, these studies consistently reveal a pronociceptive role of the right, but not left, amygdala regardless of the side of the injury. Our studies extend this concept of the role of the CeA in pain modulation in the absence of injury. Interestingly, neurons in the right lateral capsular division of the central amygdala (CeLC) have much larger receptive fields for nociceptive inputs than left CeLC neurons, including whole-body receptive fields even in injury-free rats, 33 Figure 6. Nor-BNI administered into the RVM before BLS did not ameliorate the loss of DNIC. After BLS, rats primed with morphine had a significant loss of DNIC compared with saline-primed rats in the left (A) and combined left and right (C) hind paw measures. In the right hind paw measurement (B), only the morphine/vehicle group had a significant loss of DNIC after BLS; however, the morphine/nor-BNI treatment group did not significantly differ from the morphine/vehicle group at any timepoint (A-C). At the 20-minute DNIC timepoint (D), there was a significant effect of priming (P 5 0.0246), but a Tukey post hoc test for multiple comparisons found that neither of the morphineprimed groups had significantly different DNIC from saline-primed controls at this post-BLS timepoint. **P , 0.01, *P , 0.05 significant difference between the saline/vehicle group and other treatment groups. n 5 6 saline/vehicle, 6 saline/nor-BNI, 9 morphine/vehicle, 6 morphine nor-BNI. Data analyzed using 3-way analysis of variance with Sidak correction for multiple comparisons (A-C) or 2-way analysis of variance followed by Tukey test for multiple comparisons (D). BL, baseline; BLS, bright light stress; DNIC, diffuse noxious inhibitory controls; nor-BNI, nor-binaltorphimine; RVM, rostral ventromedial medulla. Figure 7 . Dynorphin A levels are elevated in the right CeA of morphine-primed rats after stress. Morphine-primed rats exposed to bright light stress showed a loss of DNIC compared with saline-primed rats immediately before tissue collection (A). Dynorphin A levels were significantly increased (P 5 0.0227, df 5 14) in the right central nucleus of the amygdala (RCeA) of morphine-primed rats at the 20-minute timepoint of the DNIC timecourse compared with vehicleprimed rats. Quantified dynorphin A levels were not significantly different between saline-primed and morphine-primed rats at this timepoint in other a finding that may be relevant to DNIC that occurs independently of stimulus location. Descending pathways from the SRD to the spinal dorsal horn are, however, thought to be ipsilateral. 72, 84 In morphine-primed animals, DNIC was observed in both hind paws. Nevertheless, blockade of KOR signaling in the right CeA prevented the stress-induced loss of DNIC in either hind paw suggesting a generalized sensitized state induced by systemic morphine and amygdala lateralization in the modulation of stress-induced functional pain that corresponds with injury models.
After morphine priming, we found that stress produced an increase in dynorphin A content in both amygdalae that reached significance in the right CeA. We had hypothesized that dynorphin A content would also be higher in the hypothalamus after stress in primed animals but this was not observed. It is possible that dynorphin A levels would be elevated in specific regions of the hypothalamus, but we did not differentiate specific nuclei and we were restricted by the use of a coronal section that did not include the entire hypothalamus. We previously reported elevated dynorphin A levels in the left and right CeA after stress in sumatriptan-primed rats 90 even though a KOR antagonist normalized stress-induced allodynia only in the right CeA. 90 Although quantification of total dynorphin A does not mean that the peptide is released our previous study also found increased pKOR in both the left and right CeA. 90 It seems likely that after priming, stress increases dynorphin A levels in the CeA bilaterally, but only the right CeA participates in pain modulation.
The diminished CPM/DNIC response observed in FPS patients is frequently interpreted as reflecting a loss of descending inhibition. An alternate, but equally plausible, interpretation is that this outcome could result from enhanced descending facilitation. A role for the RVM has not generally been supported in DNIC. 4 Recently, Okada-Ogawa et al. 64 demonstrated that RVM inactivation restored the loss of DNIC in rats primed with morphine, possibly reflecting inhibition of ON cell firing and consistent with the interpretation that enhanced facilitation may promote a loss of DNIC. The KOR is thought to be expressed on RVM OFF and NEUTRAL, rather than ON cells. 89 Kappa opioid receptors are G i coupled and previous work has demonstrated inhibition of OFF cell discharge with KOR agonists in the RVM. 56 Thus, blockade of RVM KORs should disinhibit OFF cells to enhance, rather than inhibit, descending inhibition. In this study, we did not observe a stress-induced increase in RVM dynorphin A levels in morphine-primed rats and RVM administration of a KOR antagonist did not alter DNIC. These data provide further support for the conclusion that the loss of DNIC results from enhanced facilitation that may mask competing descending inhibition.
Our data are consistent with the possibility that enhanced descending facilitation arising, in part, from stress-related KOR signaling in the right CeA after induction of a sensitized state due to morphine, is a key amplification mechanism that may promote functional pain conditions. We previously reported that enhanced descending facilitation is essential in maintaining chronic neuropathic pain. 11 Patients with FPS demonstrating a loss of CPM may therefore be especially vulnerable to chronification of pain and may demonstrate higher response outcomes to treatments that reduce descending facilitation. To date, specific mechanisms targeting descending facilitation have not been reported. Here, we demonstrate a key role of KOR signaling in a lateralized descending circuit that may be effectively targeted for the treatment of stress-related pain disorders. Importantly, novel potent, selective, and reversible KOR antagonists such as BTRX-335140 are advancing in development. 51, 86 
